Reversal of P-glycoprotein-mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line

Japanese Journal of Cancer Research

Volumn 93, Issue 9, 2002, Pages 1037-1046

  Enokida, Hideki ^a   Gotanda, Takenari ^a   Oku, Shoichi ^a   Imazono, Yoshiharu ^a   Kubo, Hiroyuki ^a   Hanada, Toshikatsu ^b   Suzuki, Shigenori ^c   Inomata, Kouhei ^c   Kishiye, Takao ^d   Tahara, Yoshiyuki ^d   Nishiyama, Kenryu ^a   Nakagawa, Masayuki ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b OITA UNIVERSITY   (Japan)

^c TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^d NISSHIN SEIFUN GROUP INC   (Japan)

Author keywords

Bladder cancer; Multidrug resistance; Synthetic isoprenoid

Indexed keywords

ALPHA TUBULIN; AZIDOPINE; BENZENE; BETA TUBULIN; CEPHARANTHINE; CYCLOHEXANE; DNA TOPOISOMERASE INHIBITOR; GLYCOPROTEIN P; ISOPRENOID; LUNG RESISTANCE PROTEIN; N,N' BIS(3,4 DIMETHOXYBENZYL) N SOLANESYLETHYLENEDIAMINE; PACLITAXEL; TRITIUM; VERAPAMIL; VINCA ALKALOID; ANTINEOPLASTIC AGENT; ISOPRENOID PHOSPHATE SUGAR; RIBONUCLEOPROTEIN; TERPENE; TUBULIN; TUMOR PROTEIN;

ARTICLE; ASSAY; BLADDER CANCER; CANCER CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TRANSPORT; HUMAN; HUMAN CELL; INHIBITION KINETICS; MULTIDRUG RESISTANCE; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN POLYMERIZATION; WESTERN BLOTTING; BLADDER TUMOR; CELL CULTURE; DRUG RESISTANCE; IMMUNOBLOTTING; METABOLISM; PATHOLOGY; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOBLOTTING; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PACLITAXEL; POLYISOPRENYL PHOSPHATE SUGARS; STRUCTURE-ACTIVITY RELATIONSHIP; TERPENES; TUBULIN; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 0036747416     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2002.tb02481.x     Document Type: Article

References (45)

1. Bremnes, R. M., Sundstrom, S., Vilsvik, J. and Aasebo, U. Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer. J. Clin. Oncol., 19, 3532-3538 (2001).
2. Riccardi, A., Pugliese, P., Danova, M., Brugnatelli, S., Grasso, D., Giordano, M., Bernardo, G., Giardina, G., Fava, S., Montanari, G., Pedrotti, C., Trotti, G., Rinaldi, E., Poli, M. A. and Tinelli, C. A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01). Br. J. Cancer, 85, 141-146 (2001).
3. Prince, H. M., Rischin, D., Quinn, M., Allen, D., Planner, R., Neesham, D., Gates, P. and Davison, J. Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study. Gynecol. Oncol., 81, 216-224 (2001).
4. Hurwitz, C. A., Strauss, L. C., Kepner, J., Kretschmar, C., Harris, M. B., Friedman, H., Kun, L. and Kadota, R. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. J. Pediatr. Hematol. Oncol., 23, 277-281 (2001).
5. Haas, N., Roth, B., Garay, C., Yeslow, G., Entmacher, M., Weinstein, A., Rogatko, A., Babb, J., Minnitti, C., Flinker, D., Gillon, T. and Hudes, G. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. Urology, 58, 59-64 (2001).
6. Vaishampayan, U., Flaherty, L., Du, W. and Hussain, M. Phase II evaluation of paclitaxel, alpha-interferon, and cisretinoic acid in advanced renal cell carcinoma. Cancer, 92, 519-523 (2001).
7. Meluch, A. A., Greco, F. A., Burris, H. A., 3rd, O'Rourke, T., Ortega, G., Steis, R. G., Morrissey, L. H., Johnson, V. and Hainsworth, J. D. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Peal Cancer Research Network. J. Clin. Oncol., 19, 3018-3024 (2001).
8. Horwitz, S. B., Cohen, D., Rao, S., Ringel, I., Shen, H. J. and Yang, C. P. Taxol: mechanisms of action and resistance. J. Natl. Cancer Inst. Monogr., 15, 55-61 (1993).
9. Dumontet, C. and Sikic, B. I. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol., 17, 1061-1070 (1999).
10. Zhou, J., Cheng, S. C., Luo, D. and Xie, Y. Study of multidrug resistant mechanism in a taxol-resistant hepatocellular carcinoma QGY-TR 50 cell line. Biochem. Biophys. Res. Commun., 280, 1237-1242 (2001).
11. Bhalla, K., Huang, Y., Tang, C., Self, S., Ray, S., Mahoney, M. E., Pormathpur, V., Tourkina, E., Ibrado, A. M. and Bullock, G. Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia, 8, 465-475 (1994).
12. Ohta, S., Nishio, K., Kubota, N., Ohmori, T., Funayama, Y., Ohira, T., Nakajima, H., Adachi, M. and Saijo, N. Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn. J. Cancer Res., 85, 290-297 (1994).
13. Fardel, O., Lecureur, V. and Guillouzo, A. The P-glycoprotein multidrug transporter. Gen. Pharmacol., 27, 1283-1291 (1996).
14. Ford, J. M. and Hait, W. N. Pharmacologic circumvention of multidrug resistance. Cytotechnology, 12, 171-212 (1993).
15. Wingo, P. A., Tong, T. and Bolden, S. Cancer statistics, 1995. CA Cancer J. Clin., 45, 8-30 (1995).
16. Taya, T., Kobayashi, T., Tsukahara, K., Uchibayashi, T., Naito, K., Hisazumi, H. and Kuroda, K. In vitro culture of malignant tumor tissues from the human urinary tract. Jpn. J. Urol., 68, 1003-1010 (1977).
17. Scheper, R. J., Broxterman, H. J., Scheffer, G. L., Kaaijk, P., Dalton, W. S., van Heijningen, T. H., van Kalken, C. K., Slovak, M. L., de Vries, E. G., van der Valk, P., Meijer, C. J. and Pinedo, H. M. Overexpression of a M(r) 110,000 vesicular in non-P-glycoprotein-mediated multidrug resistance. Cancer Res., 53, 1475-1479 (1993).
18. Rome, L. H., Kedersha, N. L. and Chugani, D. C. Unlocking vaults: organelles in search of function. Trends Cell Biol., 1, 47-50 (1991).
19. Chugani, D. C., Kedersha, N. L. and Rome, L. H. Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. J. Cell Sci., 106, 23-29 (1993).
20. Schuurhuis, G. J., Broxterman, H. J., de Lange, J. H., Pinedo, H. M., van Heijningen, T. H., Kuiper, C. M., Scheffer, G. L., Scheper, R. J., van Kalken, C. K., Baak, J. P. and Lankelma, J. Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br. J. Cancer, 64, 857-861 (1991).
21. Kitazono, M., Okumura, H., Ikeda, R., Sumizawa, T., Furukawa, T., Nagayama, S., Tani, A., Takao, S., Aikou, T. and Akiyama, S. Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells. Int. J. Cancer, 91, 126-131 (2001).
22. Nakagawa, M., Yamaguchi, T., Ueda, H., Shiraishi, N., Komiyama, S., Akiyama, S., Ogata, J. and Kuwano, M. Potentiation by vitamin A of the action of anticancer agents against murine tumors. Jpn. J. Cancer Res., 76, 887-894 (1985).
23. Nakagawa, M., Akiyama, S., Yamaguchi, T., Shiraishi, N., Ogata, J. and Kuwano, M. Reversal of multidrug resistance by synthetic isoprenoids in the KB human cancer cell line. Cancer Res., 46, 4453-4457 (1986).
24. Yamaguchi, T., Nakagawa, M., Shiraishi, N., Yoshida, T., Kiyosue, T., Arita, M., Akiyama, S. and Kuwano, M. Overcoming drug resistance in cancer cells with synthetic isoprenoids. J. Natl. Cancer Inst., 76, 947-953 (1986).
25. Akiyama, S., Yoshimura, A., Kikuchi, H., Sumizawa, T., Kuwano, M. and Tahara, Y. Synthetic isoprenoid photoaffinity labeling of P-glycoprotein specific to multidrug-resistant cells. Mol. Pharmacol., 36, 730-735 (1989).
26. Suzuki, H., Tomida, A. and Nishimura, T. Cytocidal activity of a synthetic isoprenoid, N-solanesyl-N, N′-bis(3,4-dimethoxybenzyl)ethylenediamine, and its potentiation of antitumor drugs against multidrug-resistant and sensitive cells in vitro. Jpn. J. Cancer Res., 81, 298-303 (1990).
27. Kimiya, K., Naito, S., Soejima, T., Sakamoto, N., Kotoh, S., Kumazawa, J. and Tsuruo, T. Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ADM. J. Urol., 148, 441-445 (1992).
28. Carmichael, J., DeGraff, W. G., Gazdar, A. F., Minna, J. D. and Mitchell, J. B. Evaluation of a tetrazolium-based semi-automated colorimetric assay: assessment of chemosensitivity testing. Cancer Res., 47, 936-942 (1987).
29. Minotti, A. M., Barlow, S. B. and Cabral, F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J. Biol. Chem., 266, 3987-3994 (1991).
30. Lever, J. E. Active amino acid transport in plasma membrane vesicles from Simian virus 40-transformed mouse fibroblasts. J. Biol. Chem., 252, 1990-1997 (1977).
31. Bradford, M. A. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem., 72, 248-254 (1976).
32. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685 (1970).
33. Towbin, H., Staehelin, T. and Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA, 76, 4350-4354 (1979).
34. Kyhse, A. J. Electroblotting of multiple gels: simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. J. Biochem. Biophys. Methods, 10, 203-209 (1984).
35. Bjerrum, O. J. and Schafer-Nielsen, C. Buffer systems and transfer parameters for semidry electroblotting with a horizontal apparatus. In "Analytical Electrophoresis," ed. M. J. Dunn, pp. 315-327 (1986). Verlag Chemie, Weinheim.
36. Debenham, P. G., Kartner, K., Siminovich, L., Riordan, J. R. and Ling, V. DNA mediated transfer of multi drug resistance and plasma membrane glycoprotein expression. Mol. Cell. Biol., 2, 881-884 (1982).
37. Inomata, K., Takahashi, T., Inoue, H., Yanai, M., Yamazaki, H., Suzuki, M., Takasawa, T., Kawamura, K., Oshida, N., Ikemoto, H. and Kishiye, T. Isoprene derivatives. US Patent, No. 5756475 (1998).
38. Inomata, K., Takahashi, T., Inoue, H., Yanai, M., Yamazaki, H., Suzuki, M., Takasawa, T., Kawamura, K., Oshida, N., Ikemoto, H. and Kishiye, T. Isoprene derivatives. US Patent, No. 6011069 (2000).
39. Kartner, N., Evernden, P. D., Bradley, G. and Ling, V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature, 316, 820-823 (1985).
40. Horwitz, S. B., Cohen, D., Rao, S., Ringel, I., Shen, H. J. and Yang, C. P. Taxol: mechanisms of action and resistance. J. Natl. Cancer Inst. Monogr., 15, 55-61 (1993).
41. Giannakakou, P., Sackett, D. L., Kang, Y. K., Zhan, Z., Buters, J. T., Fojo, T. and Poruchynsky, M. S. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem., 272, 17118-17125 (1997).
42. Zordan-Nudo, T., Ling, V., Liu, Z. and Georges, E. Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance. Cancer Res., 53, 5994-6000 (1993).
43. Zhang, L., Sachs, C. W., Fine, R. L. and Casey, P. J. Interaction of prenylcysteine methyl esters with the multidrug resistance transporter. J. Biol. Chem., 269, 15973-15976 (1994).
44. Wiese, M. and Pajeva, I. K. Structure-activity relationships of multidrug resistance reversers. Curr. Med. Chem., 8, 685-713 (2001).
45. Seelig, A. How does P-glycoprotein recognize its substrates? Int. J. Clin. Pharmacol. Ther., 36, 50-54 (1998).